Funding from Blood Cancer United can lead to scientific breakthroughs that will improve and save the lives of patients.
The Blood Cancer United Research Team oversees the organization's research strategy to support cutting-edge research for every type of blood cancer, including leukemia, lymphoma, and myeloma.
Take a look at all the currently active, extraordinary Blood Cancer United-funded research projects.
11 results
Soheil Meshinchi
Fred Hutchinson Cancer Research Center
Seattle, WA
United States
Specialized Center of Research Program
Multi-modal Immunotherapeutic Targeting of AML-restricted Targets in Infants and Children
Advances in understanding and management of AML in children has been stagnant for decades. Observed improvements in survival are more directly linked to improvements in supportive care or risk identification rather than advances in therapeutics. Excitement around FDA approval of two new IDH1/2 inhibitors did not reach the pediatric oncology community given paucity or absence of such mutations in children. This also highlights the stark differences between AML in older adults and that in younger patients. Thus, “trickle down therapeutics” where therapies that are developed in older adults are used effectively in children is a flawed concept. Discoveries and therapeutic development in younger patients must be prioritized if meaningful advances are to be made in curing AML in younger patients. Given that AML in children is not a priority for the pharmaceutical companies, alternate mechanisms for advancing therapeutics in children and young adults should be implemented.
Project Term: October 1, 2021 - September 30, 2026
Who we fund
Learn more about the inspiring blood cancer scientists we support—and leading biotech companies we partner with— who are working to find cures and help blood cancer patients live longer, better lives.
Research Grants
We award grants for studies that range from basic blood cancer research to pioneering clinical trials. For more than seventy years, Blood Cancer United support has been instrumental in the development of the vast majority of breakthroughs in blood cancer treatment.
Therapy Acceleration Program ®(TAP)
TAP is a mission-driven, strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care while also generating a return on investment for the Blood Cancer United mission. TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations, and orphan indications.